Cagrilintide Peptide

Cagrilintide is a long-acting acylated analog of human amylin (IAPP — Islet Amyloid Polypeptide). Its mechanism involves:

• Amylin receptor activation: Cagrilintide binds calcitonin receptor (CTR)/RAMP1 and CTR/RAMP3 heterodimer complexes in the area postrema and nucleus tractus solitarius (NTS) of the brainstem — distinct from the hypothalamic targets of GLP-1 agonists
• Appetite suppression: Amylin receptor activation in the area postrema triggers satiety signaling through noradrenergic and dopaminergic projections to the hypothalamic appetite centers
• Gastric emptying delay: Like GLP-1, amylin slows gastric emptying, contributing to post-prandial satiety
• Glucagon suppression: Amylin suppresses post-prandial glucagon secretion, reducing hepatic glucose output

Acylation for once-weekly dosing: Native amylin has a half-life of ~15 minutes and aggregates readily (amyloid formation). Cagrilintide is engineered with specific amino acid substitutions that prevent aggregation and a fatty acid conjugation that enables albumin binding, extending the half-life to ~7 days for once-weekly administration.

Structural design rationale: Cagrilintide is built on a chimeric scaffold combining structural elements of human amylin and salmon calcitonin. Salmon calcitonin shares strong N-terminal homology with amylin and is highly resistant to amyloid aggregation; incorporating its stabilizing residues — including proline substitutions in the amyloidogenic 20-29 segment — produces an amylin agonist with markedly improved solution stability. The intramolecular disulfide bridge between Cys2 and Cys7 stabilizes the N-terminal loop that engages the calcitonin receptor (CTR) component of the amylin receptor complex.

Acylation chemistry: A C18 dicarboxylic (octadecanedioic) fatty acid is conjugated through a γ-glutamate spacer and two oligoethylene-glycol (OEG) units to a lysine ε-amine. This is the same general protraction strategy used in semaglutide (C18 diacid) and insulin degludec. The diacid moiety binds reversibly to fatty acid binding sites on human serum albumin (HSA), creating a circulating depot that protects against renal filtration and proteolysis. The result is a plasma half-life of roughly one week — orders of magnitude longer than native amylin (~13 min) or pramlintide (~50 min).

Receptor pharmacology: The functional amylin receptor is a heteromer of the calcitonin receptor (CTR, a class B GPCR) with a receptor activity-modifying protein (RAMP1, RAMP2, or RAMP3), yielding AMY1, AMY2, and AMY3 subtypes. Cagrilintide displays high binding affinity at all three amylin receptor subtypes and retains activity at the parent CTR, contributing to its sustained anorectic and metabolic signaling profile. Downstream signaling proceeds through Gs/cAMP/PKA, with additional ERK1/2 recruitment depending on subtype and tissue context.

Physical handling notes: The amphipathic character imparted by the lipid tail makes cagrilintide prone to adsorption on hydrophobic surfaces at low concentrations; low-binding polypropylene tubes and mildly alkaline buffers improve recovery in analytical workflows. For research use only.

Lyophilized powder storage: Cagrilintide in lyophilized form is best maintained at -20°C in a sealed, desiccated container, where it retains ≥98% chromatographic purity for approximately 24 months. For shorter research timelines (under 30 days), storage at 2-8°C is acceptable provided the vial remains tightly sealed and protected from atmospheric moisture. For long-term archival (>24 months), -80°C storage is recommended to minimize any slow oxidative or hydrolytic degradation of the lipid tether.

Reconstituted solution: Once dissolved in bacteriostatic water, sterile water for injection, or 0.9% sodium chloride, cagrilintide should be stored at 2-8°C and used within approximately 21 days. Repeated freeze-thaw cycles of reconstituted material are strongly discouraged, as they accelerate aggregation kinetics and can reduce receptor-binding potency. Reconstitution buffers with mildly basic pH (7.4-8.0) generally give superior solubility because the C-terminal amide and lysine-conjugated diacid favor deprotonated, soluble forms.

Engineered aggregation resistance: Native human amylin (IAPP) is notoriously prone to forming β-sheet amyloid fibrils — a property that complicates formulation of pramlintide (the proline-substituted human analog) and contributes to islet amyloid deposition in type 2 diabetes. Cagrilintide was designed on a backbone modeled on salmon calcitonin/amylin chimera principles, with multiple substitutions (including proline introductions and a stabilized disulfide bridge between Cys2 and Cys7) that disrupt the amyloidogenic 20-29 region. Biophysical studies of related amylin analogs show that these substitutions dramatically slow ThT-positive fibril formation compared with native hIAPP.

Acylation and albumin binding: A C18 diacid fatty chain attached via a γGlu-OEG-OEG linker to a lysine residue allows cagrilintide to bind reversibly to circulating serum albumin. In solution, this acylation also reduces self-association and protects the peptide from rapid proteolytic clearance. The same chemical strategy underpins the long half-lives of semaglutide and insulin degludec. In storage, the lipid moiety contributes modestly to thermal stability but can promote adsorption to hydrophobic surfaces — therefore low-protein-binding polypropylene vials are preferred over glass for dilute working stocks.

Handling best practices:

• Allow vials to equilibrate to room temperature before opening to prevent moisture condensation on the lyophilizate.
• Reconstitute slowly down the vial wall; avoid vigorous vortexing which can shear the peptide and nucleate aggregation.
• Filter sterilize through a low-protein-binding 0.22 μm PVDF membrane if downstream applications require sterility.
• Aliquot reconstituted material to minimize repeated puncture of the septum and limit oxidative exposure.
• Monitor for visible turbidity or particulates; cagrilintide solutions should remain clear and colorless.

Quality monitoring: For laboratories performing extended studies, periodic re-analysis by RP-HPLC and mass spectrometry is recommended to confirm peptide integrity. Degradation typically manifests first as oxidation at methionine or histidine residues, deamidation at asparagine/glutamine positions, or cleavage of the fatty acid linker. This material is supplied strictly for in vitro and preclinical laboratory research and is not for human or veterinary use.